Thiazolidinediones and cardiovascular outcomes in type 2 diabetes

被引：6
|
作者：
Singh, Sonal [1 ]
Furberg, Curt D. [2 ]
机构：
[1] Wake Forest Univ, Sch Med, Gen Internal Med Sect, Winston Salem, NC 27157 USA
[2] Wake Forest Univ, Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27157 USA
来源：
HEART | 2009年 / 95卷 / 01期
关键词：
ROSIGLITAZONE; PIOGLITAZONE; MELLITUS; RISK; METAANALYSIS; EVENTS; ASSOCIATION; PREVENTION; STATEMENT; THERAPY;
D O I：
10.1136/hrt.2008.155507
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1 / 3
页数：3
相关论文
共 50 条
  • [31] Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
    Drexler, Andrew J.
    Nesto, Richard W.
    Abrahamson, Martin J.
    Bakris, George
    Bell, David
    Brunzell, John
    Dandona, Paresh
    Davidson, Jaime
    Fonseca, Vivian
    Fowler, Michael
    Frye, Robert
    Giles, Thomas
    Haffner, Steven
    Hollenberg, Norman
    Hsueh, Willa
    Law, Ronald
    Plutzky, Jorge
    Ratner, Robert
    Reusch, Jane
    Selwyn, Andrew
    Sowers, James
    Wyne, Kathleen
    Young, Lawrence H.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2005, 3 (02) : 147 - 173
  • [32] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes
    Zweck, Elric
    Westenfeld, Ralf
    Szendroedi, Julia
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2075 - 2076
  • [33] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Rosenstein, Robert
    Hough, Augustus
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1093 - 1094
  • [34] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [35] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (22): : 2117 - 2128
  • [36] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Marso, Steven P.
    Bain, Stephen C.
    Consoli, Agostino
    Eliaschewitz, Freddy G.
    Jodar, Esteban
    Leiter, Lawrence A.
    Lingvay, Ildiko
    Rosenstock, Julio
    Seufert, Jochen
    Warren, Mark L.
    Woo, Vincent
    Hansen, Oluf
    Holst, Anders G.
    Pettersson, Jonas
    Vilsboll, Tina
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19): : 1834 - 1844
  • [37] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [38] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
  • [39] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
    Leitner, H.
    JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
  • [40] Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Ipp, Eli
    Genter, Pauline
    Childress, Kristin
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (09): : 890 - 891
12345